series number,sample number,clinical condition,treatment,sex,age,tissue,patient id,cell type,notes
GSE168859,GSM5171620,T-LGLL,pretreatment,F,71,PBMC,UPN24,,pretreatment
GSE168859,GSM5171621,T-LGLL,alemtuzumab,F,71,PBMC,UPN24,,posttreatment
GSE168859,GSM5171622,T-LGLL,pretreatment,M,61,PBMC,UPN10,,pretreatment
GSE168859,GSM5171623,T-LGLL,alemtuzumab,M,61,PBMC,UPN10,,posttreatment
GSE168859,GSM5171624,T-LGLL,pretreatment,F,29,PBMC,UPN19,,pretreatment
GSE168859,GSM5171625,T-LGLL,alemtuzumab,F,29,PBMC,UPN19,,posttreatment
GSE168859,GSM5171626,Healthy,,F,39,PBMC,Healthydonor1,,
GSE168859,GSM5171627,Healthy,,F,71,PBMC,Healthydonor2,,
GSE168859,GSM5171628,T-LGLL,pretreatment,F,72,PBMC,UPN18,,pretreatment
GSE168859,GSM5171629,T-LGLL,alemtuzumab,F,72,PBMC,UPN18,,posttreatment
GSE168859,GSM5171630,T-LGLL,pretreatment,M,77,PBMC,UPN4,,pretreatment
GSE168859,GSM5171631,T-LGLL,alemtuzumab,M,77,PBMC,UPN4,,posttreatment
GSE168859,GSM5171632,T-LGLL,pretreatment,M,43,PBMC,UPN17,,pretreatment
GSE168859,GSM5171633,T-LGLL,alemtuzumab,M,43,PBMC,UPN17,,posttreatment
GSE168859,GSM5171634,Healthy,,F,55,PBMC,Healthydonor3,,
GSE168859,GSM5171635,Healthy,,M,68,PBMC,Healthydonor4,,
GSE168859,GSM5171636,T-LGLL,pretreatment,F,51,PBMC,UPN1,,pretreatment
GSE168859,GSM5171637,T-LGLL,alemtuzumab,F,51,PBMC,UPN1,,posttreatment
GSE168859,GSM5171638,T-LGLL,pretreatment,M,82,PBMC,UPN12,,pretreatment
GSE168859,GSM5171639,T-LGLL,alemtuzumab,M,82,PBMC,UPN12,,posttreatment
GSE168859,GSM5171640,T-LGLL,pretreatment,M,51,PBMC,UPN8,,pretreatment
GSE168859,GSM5171641,T-LGLL,pretreatment,F,27,PBMC,UPN13,,pretreatment
GSE168859,GSM5171642,Healthy,,F,41,PBMC,Healthydonor5,,
GSE168859,GSM5171643,Healthy,,M,60,PBMC,Healthydonor6,,
GSE168859,GSM5171644,T-LGLL,alemtuzumab,M,51,PBMC,UPN8,,posttreatment
GSE168859,GSM5171645,T-LGLL,alemtuzumab,F,27,PBMC,UPN13,,posttreatment
GSE168859,GSM5171646,T-LGLL,pretreatment,F,66,PBMC,UPN14,,pretreatment
GSE168859,GSM5171647,T-LGLL,alemtuzumab,F,66,PBMC,UPN14,,posttreatment
GSE168859,GSM5171648,T-LGLL,pretreatment,F,48,PBMC,UPN15,,pretreatment
GSE168859,GSM5171649,T-LGLL,alemtuzumab,F,48,PBMC,UPN15,,posttreatment
GSE168859,GSM5171650,T-LGLL,pretreatment,M,39,PBMC,UPN6,,pretreatment
GSE168859,GSM5171651,Healthy,,M,41,PBMC,Healthydonor7,,
